DA
SCLN

Denali Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Denali Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-135
Closed -$1K – 294
2014
Q4 		$1K Buy
+135
New +$1.09K ﹤0.01% 245

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Denali Advisors's SCLN Position: Q1 2015 in Review

Denali Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2015, closing a stake of 135 shares — an estimated $1K sold.

Denali Advisors first reported a position in SCLN in Q4 2014 and held it in 1 quarter. The position peaked at $1K in Q4 2014. 130 funds tracked by Wall St. Rank hold SCLN as of Q1 2015.

  • Denali Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • Denali Advisors sold 135 Sciclone Pharmaceuticals Inc shares in Q1 2015, an estimated $1K.
  • Denali Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q4 2014 and held it in 1 quarter.
  • Denali Advisors's Sciclone Pharmaceuticals Inc position peaked at $1K in Q4 2014.
  • 130 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2015.

Based on Denali Advisors's 13F filing for Q1 2015, filed 17 Apr 2015.